Miles M. Landis, MD
Disclosures: Nothing to disclose

CURRICULUM VITAE

Miles Mayer Landis, MD

 

OFFICE AND  RESEARCH CENTER ADDRESS:                                                                                                                Miles M. Landis, MD dba Advent Health Lake Mary Pediatrics                                                                            2505 Junior Street                                                                                                                                               Orange City, FL 32763

PROFESSIONAL EXPERIENCE:                                                                                                                                  

2017-present                                                Practicing pediatrician and Medical Director Outpatient     

                                                                      Pediatrics AdventHealth Medical Group

2008-Present                                                        Principal Investigator                                                                                                                                                          Miles M. Landis, MD dba Advent Health Lake Mary Pediatrics                                                                                    Orange City, FL 32763

1988-2017                                                        Private Practice, Pediatrics                                                                                                                                            Founder                                                                                                                                                                          Miles M. Landis, MD, PA dba Lake Mary Pediatrics                                                                                                  Orange City, FL, Lake Mary, FL and College Park, FL

1986-1988                                                        General Pediatrician                                                                                                                                                          Pediatric Medical Group                                                                                                                                            Union, NJ

1976-1979                                                        Research Assistant                                                                                                                                                          The Rockefeller University                                                                                                                                            New York, NY

EDUCATION:                                                                                                                                                                1986                                                                      The Children’s Hospital of Buffalo                                                                                                                              Buffalo, New York                                                                                                                                                          Internship, Residency: Pediatrics

1983                                                                      University of Buffalo                                                                                                                                                          Buffalo, New York                                                                                                                                                          Doctor of Medicine                                                                                     

1976                                                                      Rensselaer Polytechnic Institute                                                                                                                                            Troy, New York                                                                                                                                                                        Bachelor of Science, cum laude

PROFESSIONAL MEMEMBERSHIPS/ORGANIZATIONS:                                                                                                  Fellow, American Academy of Pediatrics

LICENSES:                                                                                                                                                                                            Florida                                                                      ME51571

 

CERTIFICATIONS:                                                                                                                                          American Board of Pediatrics                                                                                                                                Autism Diagnostic Interview-Revised (ADIR)                                                                                                     Impact test

Positions Held:

2017-present: Director, Outpatient Pediatrics AdventHealth Medical Group

2000-2017: President, Miles M Landis, MD, PA

 

HOSPITAL AFFILIATIONS:                                                                                                                                      Advent Health Children’s Hospital, Advent Hospital for Women

Arnold Palmer Children’s Hospital, Winnie Palmer Hospital for Women and Babies

 

RESEARCH EXPERIENCE:                                                                                                                                             

  1. Hepatic Porphyrias. The Rockefeller University. 1976-1979.
  2. Circadian Rhythmicity of Intestinal Disaccharidases. Department of Pediatric Gastroenterology Children’s Hospital of Buffalo, Buffalo, NY. 1985.
  3. Concerta FOCUS Trial. McNeil. 2001.
  4. Omnicef Trail. 2002
  5. Influenza Vaccine. Data analysis for influenza vaccine usage in 4000 children within our own practice. MedImmune. 2008.
  6. C-07-40: An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in the USA. Alcon Research. Principal Investigator. December 2008 – March 2010.
  7. MI-CP147: A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-559, a Live Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus in Healthy 1 to <24 Month-Old Children. MedImmune. Principal Investigator. May 2009 – April 2010.
  8. 00101/Autism: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of LUMINENZ-ATTM (CM-AT) In Children with Autism.  Curemark.  Principal Investigator. May 2009 – September 2011.
  9. MK0476-377: A Double-Blind, Placebo-Controlled, Multicenter, Crossover Study to Evaluate the Effects of a Single Oral Dose of Montelukast, Compared with Placebo, on Exercise-Induced Bronchoconstriction (EIB) in Pediatrics Patients Aged 4 to 14 years.  Merck. Principal Investigator. October 2009 – October 2010.
  10. 112957 Hib-097: A Phase III, Randomized, Multicenter, Double-Blinded study for the immunogenicity and consistency evaluation of 3 lots of GSK Biologicals’ Haemophilus Influenzae type b (Hib) conjugate vaccine and single blind and controlled for the evaluation of safety and immunogenicity of GSK Biologicals’ Hib vaccine 208108 compared to the monovalent Hib vaccine ActHIB and open for comparison with the cobined DTPa-IPV-Hib vaccine Pentacel when administered to healthy infacts at 2, 4, 6, and 15-18 months of age with recommended co-administrations at separate sites.  GlaxoSmithKline. Principal Investigator. October 2009 – March 2013. 
  11. D589GC00001: Phase 2, Double-Blind, Randomized, Parellel-group, Placebo-controlled, Multicenter Study, comparing Budesonide pMDI 160 ug Bid with Placebo: a 6-week Efficacy and Safety Study in Children aged 6 to <12 years with Asthma.  AstraZeneca. Principal Investigator. April 2010 – 2013.
  12. V114-003: Phase II, A Multicenter, Double-Blind Study of the Safety, Tolerability and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13TM in Healthy Infants.  Merck.  Principal Investigator. October 2010 – June 2012.
  13. MLN-MD-14: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Withdrawal Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran In Pediatrics Patients with Primary Fibromyalgia.  Forest Laboratories.  Principal Investigator.  April 2011 – June 2012.
  14. MLN-MD-29: A Phase II, Multicenter, Open-Label, 52-Week Extension Study to Evaluate the Safety and Efficacy of Milnacipran in Pediatrics Patient with Primary Fibromyalgia.  Forest Laboratories.  Principal Investigator.  April 2011 – June 2012.
  15. 00102/Autism: A Phase III Open Label Extension Study of LUMINENZ-ATTM (CM-AT) in Children with Autism.  Curemark.  Principal Investigator.  April 2011 –
  16. 209AS208: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects with Autism Spectrum Disorders.  Seaside Therapeutics, Inc.  Principal Investigator. October 2011 – January 2013.
  17. 209AS209: A Phase II, Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects with Autism Spectrum Disorders.  Seaside Therapeutics, Inc. Principal Investigator. October 2011 – July 2013.
  18. 209FX301: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Adolescents and Adults with Fragile X Syndrome.  Seaside Therapeutics, Inc. Principal Investigator. October 2011 – May 2013.
  19. 209FX302: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Adolescents and Adults with Fragile X Syndrome.  Seaside Therapeutics, Inc. Principal Investigator. October 2011 – August 2013.
  20. 209FX303: A Phase III, Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subject with Fragile X Syndrome.  Seaside Therapeutics, Inc.  Principal Investigator. October 2011 – August 2013.
  21. MEM-MD-68: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder not Otherwise Specified (PDD-NOS) Previously Treated with Memantine.  Forest Research institute.  Principal Investigator. July 2012 – March 2014.
  22. MEM-MD-69: An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder not Otherwise Specified (PDD-NOS).  Forest Research institute.  Principal Investigator.  July 2012 – January 2014.
  23. MEM-MD-91: An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder not Otherwise Specified (PDD-NOS).  Forest Research institute.  Principal Investigator.  July 2012 – January 2014.
  24. AL06: Growth and Tolerance of Young Infants Fed Infant Formulas.  Abbott Nutrition.  Principal Investigator.  April 2013 – November 2013.
  25. 117119 (DTPA-HBV-IPV-135): A Phase III, Randomized, Open-Label, Controlled, Multicenter study to evaluate immunogenicity and safety of GSK Biologicals’ Infanrix Hexa vaccine when administered to healthy infants as primary vaccination at 2, 4, and 6 months of age, co-administered with Prenvar® and Rotatrix with a booster dose of GSK Biologicals’ Infanrix® and Hiberix vaccines at 15-18 months of age.  GlaxoSmithKline.  Principal Investigator.  March 2014 –
  26. NEU-CH-7911: A Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety and Circadin® to Alleviate Sleep Disturbances in Children with Neurodevelopmental Disabilities.  Neurim Pharmaceuticals Ltd. Sub-Investigator. September 2014 – June 2017.
  27. CFOR258D2416: A 26 week, Randomized, Active-Controlled Safety Study of Double-Blind Formoterol Fumarate in free combination with an inhaled corticosteroid versus an inhaled corticosteroid in adolescent and adult patients with persistent asthma.  Novartis Pharmaceuticals.  Principal Investigator.  September 2014 –
  28. 00103/Autism: A Double Blind, Randomized, Placebo Controlled Study of CM-AT for the Treatment of Autism in Children with All Levels of Fecal Chymotrypsin.  Curemark.  Principal Investigator.  June 2015 –
  29. 00104/Autism: An Extension Study of CM-AT for the Treatment of Autism in Children with All Levels of Fecal Chymotrypsin.  Curemark.  Principal Investigator.
  30. MET 42: Double Blind Trial Menquad, Meningococcal Vaccine November 2019- present

Principal Investigator